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Mutation is associated with developmental and hereditary disorders, aging, and cancer. While we understand some mu-
tational processes operative in human disease, most remain mysterious. We used Caenorhabditis elegans whole-genome se-
quencing to model mutational signatures, analyzing 183 worm populations across 17 DNA repair-deficient backgrounds
propagated for 20 generations or exposed to carcinogens. The baselinemutation rate in C. eleganswas approximately one per
genome per generation, not overtly altered across several DNA repair deficiencies over 20 generations. Telomere erosion
led to complex chromosomal rearrangements initiated by breakage–fusion–bridge cycles and completed by simultaneously
acquired, localized clusters of breakpoints. Aflatoxin B1 induced substitutions of guanines in a GpC context, as observed in
aflatoxin-induced liver cancers. Mutational burden increased with impaired nucleotide excision repair. Cisplatin and
mechlorethamine, DNAcrosslinking agents, caused dose- and genotype-dependent signatures among indels, substitutions, and
rearrangements. Strikingly, both agents induced clustered rearrangements resembling ‘‘chromoanasynthesis,’’ a replication-
based mutational signature seen in constitutional genomic disorders, suggesting that interstrand crosslinks may play a
pathogenic role in such events. Cisplatin mutagenicity was most pronounced in xpf-1 mutants, suggesting that this gene
critically protects cells against platinum chemotherapy. Thus, experimental model systems combined with genome se-
quencing can recapture and mechanistically explain mutational signatures associated with human disease.
[Supplemental material is available for this article.]
Maintenance of DNA fidelity in both germline and somatic cells is
critical to life. Genome duplication is fraught with the risk of rep-
lication errors, and this is compounded by damage to DNA from
environmental agents, ultraviolet light, ionizing radiation, and en-
dogenous by-products ofmetabolism such as reactive oxygen species.
Unchecked, the resulting mutations in somatic cells can lead to
cancer, neurodegeneration, and premature aging, as evidenced by an
increased incidence of such disorders in individuals who inherit ab-
normalities of DNA repair pathways.Mutations arising in germ cells
can lead to hereditary disease and major developmental disorders.
Given these multifarious threats to the fundament of cellular
inheritance, eukaryotes have evolved sophisticated pathways for
detecting and repairing DNA damage. Our understanding of the
mechanisms underpinning detection of DNA lesions, the relative
contribution of different repair pathways to each type of lesion,
and the regulation of pathway choice is still fragmentary. DNA
repair ideally occurs by restoring the original genetic information.
However, it is well established that some DNA repair pathways are
prone to errors and yet necessary for cellular survival. These in-
clude nonhomologous DNA end-joining (NHEJ), a repair modality
that leads to direct ligation of broken DNA ends, and translesion
synthesis (TLS), a process where error-prone polymerasesmaintain
replication opposite damaged DNA bases (for review, see Ho and
Scharer 2010). Homologous recombination is overall considered to
be an error-free pathway of DNA double-strand break repair, but
DNA synthesis associated with gene conversion leads to increased
mutation rates, as is the case for synthesis-dependent strand
annealing (SDSA) and break-induced replication (BIR) repair
(Smith et al. 2007; Hicks et al. 2010; Deem et al. 2011).
A ‘‘mutational process’’ results from the interplay of DNA dam-
aging agents, either endogenous or exogenous, with local DNA
chemistry and repair pathways. Such processes leave distinct ‘‘signa-
tures’’ in the genome, which we can define using a number of vari-
ables, including type of event, local sequence context, chromatin
landscape, timing, genomic clustering, and imprint of attempted
DNA repair. In somatic cells, these signatures can be deciphered from
cancer genomes (Stratton et al. 2009; Alexandrov et al. 2013) or single
somatic cell sequencing (Welch et al. 2012); in the germline, they are
best inferred from sequencing parent–child trios (Kong et al. 2012).
They differ across tumor types, among individuals within a tumor
type, andevenamongcloneswithinan individual’s tumor. Systematic
sequencing of cancer and germline genomes has enabled description
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of these signatures in exquisite detail, and many new mutational
processes have been delineated, often with surprising properties.
The leap from describing a mutational signature to a mecha-
nistic understanding of its etiology is challenging. For several, we
have a reasonably complete picture: C>T mutations at CpG di-
nucleotides are due to spontaneous deamination of methylated
cytosine (Waters and Swann 2000); C>T substitutions in skin
cancers result from the failure to repair UV-induced cyclobutane
pyrimidine dimers (Pfeifer et al. 2005; Pleasance et al. 2010a); and
microsatellite instability arises in cells with loss of the mismatch
repair pathway (Aaltonen et al. 1993; Ionov et al. 1993; Thibodeau
et al. 1993). For themajority ofmutational signatures, however, we
have limited insights into their etiology, resulting in a proliferation
of neologisms that describe their genomic manifestations rather
than the underlying (and unknown) mechanisms. These include
‘‘kataegis’’: referring to a processive clustering of cytosine muta-
tions in a TpC context oftennear genomic rearrangements, thought
to be caused by DNA-editing enzymes (Nik-Zainal et al. 2012a,b;
Roberts et al. 2012, 2013; Burns et al. 2013; Taylor et al. 2013);
‘‘chromoplexy’’: balanced chains of rearrangements across multi-
ple chromosomes in prostate cancer (Baca et al. 2013); ‘‘chromo-
thripsis’’: clusters of tens to hundreds of localized genomic rear-
rangements occurring in a single catastrophic event in 2%–3% of
all cancers (Stephens et al. 2011); and ‘‘chromoanasynthesis’’: a
phenomenon occurring in the germline, driving localized gains
and losses of chromosomal material through a replication-based
mechanism (Liu et al. 2011a,b).
Experimental model systems such as yeast and Caenorhabditis
elegans have a tradition in the study of mutational processes, due to
their convenient life cycles, compact genome, and ease of genetic
manipulation. The ;100 million base pair C. elegans genome was
the first animal genome to be sequenced (TheC. elegans Sequencing
Consortium 1998). Mutational signatures have been investigated
for ethylmethanesulfonate (EMS) andN-ethyl-N-nitrosourea (ENU),
alkylating agents commonly used for forward genetic screens
(Flibotte et al. 2010). EMS and ENU mutagenesis approaches have
been recently used systematically, aiming for generating multiple
mutations in every worm gene. The sequencing of ;1000 strains
was used to generate >800,000 unique single-nucleotidemutations
and thousands of indels (Thompson et al. 2013). Using classic
genetic methods, mutation frequencies have also been estimated
in response to ionizing radiation (Rosenbluth et al. 1985) and as a
consequenceofDNA repair deficiencies in the dog-1helicase and the
mrt-2 and clk-2 checkpoint genes (Harris et al. 2006; Kruisselbrink
et al. 2008; Zhao et al. 2008).Moreover, limited genome sequencing
was used to estimate mutation rates in C. elegans (Cheung et al.
2002; Denver et al. 2006, 2009; Harris et al. 2006) and studies were
more recently extended genome-wide to strains deficient for
translesion polymerases (Koole et al. 2014; Roerink et al. 2014). An
initial study focused on yeast mutant accumulation, provided a
baseline mutation rate, and showed increased mutagenesis for
several repair deficiencies (Serero et al. 2014). Nevertheless, in
general, though, the DNA repair community largely relies on
toxicity assays that score for reduced survival to study conse-
quences of carcinogen exposure and/or loss of repair fidelity. These
assays and assays that rely on single locus reporter systems lack the
genomic breadth to characterize a full mutational signature. With
the advent of whole-genome sequencing, however, it has become
feasible to systematically exploit these experimental systems for
a large-scale, comprehensive description of mutational signatures.
We established massively parallel sequencing of C. elegans
genomes as a model to analyze the patterns and etiology of mu-
tations arising with exposure to carcinogens and across different
DNA repair backgrounds. In total, we sequenced whole genomes
from 183 populations of worms, drawn from 17 different genetic
backgrounds (wild-type and knockouts for various DNA repair and
DNA damage response genes) followed for 20 generations or ex-
posed in a single generation to one of three mutagens. We iden-
tified and analyzed 1559 base substitutions, 406 indels, and 281
genomic rearrangements. From these data, we extracted muta-
tional signatures that resemble those seen inhuman cancers and in
developmental genomic disorders.
Results
Mutation accumulation in wild-type and DNA
repair-deficient C. elegans
In C. elegans, knockouts have been systematically generated by the
research community and by international consortia using random
mutagenesis protocols that cause either inactivating point muta-
tions or deletions in the gene of interest (The C. elegans Deletion
Mutant Consortium 2012). We identified a set of lines with knock-
out of genes involved in DNA damage response and repair and
backcrossed these to ourN2wild-type reference strain to obtain lines
with genomes virtually identical to wild-type, except for the gene
disruption under investigation (Supplemental Material; Supple-
mental Table S1). Based on backcrossing for a minimum of six times
against the wild-type reference, we expect >98% of the genome of
wild-type and knockout worms to be identical. Stocks were frozen to
safeguard against mutation accumulation between experiments.
To study spontaneous mutation accumulation rates per gen-
eration, we transferred a single hermaphrodite of a given genotype
onto a plate (P0 generation) (Fig. 1A). After 3 to 4 d, single F1 L4
animals were randomly chosen and propagated on a new plate, a
procedure repeated for 20 generations and performed in quintu-
plicate for each genotype. Since propagation is by self-fertilization,
each new generation effectively derives from a diploid zygote rep-
resenting a single-cell bottleneck, thereby enabling mutations to
be identified in shotgun sequencing data (Denver et al. 2009).
Genomic DNA from three F20 animals of each genotype was se-
quenced to a target depth of 30-fold, and compared with the ge-
nome of the founder worm using well-established bioinformatics
algorithms to call newly acquired base substitutions, small indels,
and genomic rearrangements (Nik-Zainal et al. 2012a,b).
As expected, base substitutions were the most frequent mu-
tations observed in wild-type C. elegans and most of the DNA re-
pair-deficient backgrounds analyzed (Fig. 1B; Supplemental Tables
S2–S4). Mutation rates were consistent across the replicate lines in
each given genetic background, indicating that the accumulation
of de novo mutations per se did not significantly change the ob-
served mutation rate, at least within the time course of our ex-
periment. The six possible single-base substitutions (C>A, C>G,
C>T,T>A,T>C, andT>G)occurred at broadly equal frequency (Fig. 1B),
although C>T mutations (mean, 2.8 per 20 generations per line)
were more common than other categories (range in means, 0.7–1.7
per 20 generations per line), as previously reported (Denver et al.
2009). In the ung-1 knockout line, we observed a greater proportion
of C>T transitions than in other lines (P = 0.003). This signature is
expected, because the function of UNG-1 is to eliminate uracil that
arises from spontaneous deamination of cytosine in genomic DNA
by initiating base excision repair.Without this, DNA replication can
misincorporate an adenine opposite the uracil, leading to a C>T
mutation. In the absence of UNG-1, redundant pathways may take
over in line with no overt increase in mutation frequency.
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For each round of self-fertilization, a newly acquired heterozy-
gousmutation has a 25% chance of becoming homozygous and fixed
in the line, assuming no effect on viability (Thompson et al. 2013).
Also, with each generation, a variant has a 50% chance of remaining
heterozygous and a 25% chance of being lost to the line. Allowing for
this,weusedmaximumlikelihoodmethods to estimatemutation rates
per generation in each background. We
observed a remarkably consistent average of
approximately one mutation per genome
perC. elegans generation (Supplemental Fig.
S1), approximately twice that previously
estimated (Denver et al. 2009). This dis-
crepancy in estimated rates is probably due
to the greater portionof the genome thatwe
can now access with 100-bp paired end
reads than was available in earlier experi-
ments. Based on the known developmental
lineage and germ cell expansion in adult
animals, ;15 cell divisions occur between
successive generations (Sulston et al. 1983).
We therefore estimate a spontaneous muta-
tion rate in theC. elegans germcell lineageof
;6.73 1010 per base pair per cell division,
in line with the reported rate of ;3.6 3
1010 in budding yeast (Serero et al. 2014).
Germ cell genome maintenance appears
surprisingly robust even when the ability to
initiate one of several different DNA repair
pathways is compromised. The absence of
increased mutation accumulation might
indicate that the corresponding repair mo-
dalities might be selected to cope with ex-
ogenous DNA damaging agents. However,
mutation accumulation experiments need
to be done for substantially more genera-
tions to exclude increased spontaneous
mutation rates. Also endogenous damage
levelsmight be increasedwhenworms grow
in their natural environment.
C. elegans deficient for mrt-2
develop telomere crisis and
breakage-fusion-bridge cycles
Both TRT-1, the catalytic subunit of telo-
merase, and MRT-2, the C. elegans RAD1
subunit of the conserved 9-1-1 replication
factor C-like complex, are required for telo-
mere maintenance. In addition, MRT-2 has
a role in homologous recombination and
DNAdamage checkpoint signaling (Gartner
et al. 2000). Telomeres become critically
short after propagating trt-1 and mrt-2 ho-
mozygous mutant lines for 15–25 genera-
tions (Ahmed and Hodgkin 2000; Meier
et al. 2006). Eventually, the entire mutant
strain population succumbs to sterility but
fused chromosomes have previously been
isolated, suggesting the presence of geno-
mic rearrangements near telomeres (Ahmed
and Hodgkin 2000; Meier et al. 2006; Low-
den et al. 2008). Sequencing late-generation
mrt-2 lines, we identified several lines with stable but convoluted
clusters of genomic rearrangements (Fig. 1C,D). These rearrangements
clustered near the ends of chromosomes and were associated with
multiple changes in copy-number state. We used a graph theory al-
gorithm (Greenmanet al. 2012) to infer the sequence of events leading
to these complex genomic structures (Fig. 1E; Supplemental Fig. S2).
Figure 1. Mutations in C. elegans followed for 20 generations. (A) The experimental design used three
progeny of a founder or parental (P0) animal, propagated by self-fertilization for 20 generations (F1: filial
1; F20: filial 20). The 20th generation worm was expanded to generate sufficient DNA for whole-ge-
nome sequencing. (B) Numbers and distribution of acquired mutations across wild-type (WT) and
different genetic knockout lines. Each replicate worm is shown as a separate bar, colored by the class of
variant. (Del) Deletion; (Ins) insertion; (DI) complex indel. (C ) Copy-number profile and genomic
rearrangements observed on chromosome V for an mrt-2 deficient animal. Numbers next to the ge-
nomic rearrangements refer to the inferred sequence of events. (D) Copy-number profile and genomic
rearrangements observed on chromosomes V and X for another mrt-2-deficient animal. Numbers next
to the genomic rearrangements refer to the inferred sequence of events. (E ) Proposed model for the
evolution of the copy-number changes and genomic rearrangements in C and D. A telomere crisis
precipitates several breakage-fusion-bridge (BFB) cycles, which are resolved by a cell cycle in which
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In each case, the initial rearrangements (marked ❶ in Fig.
1C–E) comprised inverted rearrangements that demarcated sharp
changes in copy number. These rearrangements most likely result
frombreakage-fusion-bridge (BFB) cycles, first described by Barbara
McClintock in maize (McClintock 1941). During these cycles, an
existing dsDNAbreak is replicated in S phase and resolved inG2 by
fusing the broken ends of the chromatids together (Supplemental
Fig. S2). This results in chromosomes that form an anaphase bridge
during cytokinesis. With completion of cell division, scission of this
bridge generates new dsDNAbreaks in the two daughter cells, and the
breakage-fusion-bridge cycle can repeat. We see evidence for a second
such cycle in the two genomes illustrated (rearrangementsmarked❷).
In bothmrt-2mutant lines, the process is completed through
simultaneous acquisition of several rearrangements (marked ❸)
(Supplemental Fig. S2). Although the number of rearrangements in
this final series of clustered events is small, the pattern bears some
resemblance to chromothripsis (Stephens et al. 2011) in that the
rearrangements are acquired simultaneously, demarcate oscillating
copy-number changes, and form a chain of linked chromosomal
segments (Korbel and Campbell 2013). This is of particular interest
because the anaphase bridge associatedwith breakage-fusion-bridge
cycles can cause micronucleus formation as the cytokinetic furrow
divides daughter cells (Pampalona et al. 2010), andmicronucleimay
sequester chromosomal fragments for DNA repair before rejoining
the main nucleus (Crasta et al. 2012; Hatch et al. 2013). Breakage-
fusion-bridge cycles may therefore increase the chance of chromo-
thripsis-type events occurring. This final event solves the initial
telomere crisis through end-to-end fusion of two chromosomes.
Taken together, then, telomere crises occurring in mrt-2-de-
ficient animals are associatedwith breakage-fusion-bridge cycles of
repair and rearrangement. Telomere attrition occurs in many
cancer types (Xu et al. 2013), but the genomic signature of break-
age-fusion-bridge repair is seen rather less frequently. It is, how-
ever, especially prominent in pancreatic cancer, accounting for
one-sixth of rearrangements in this cancer type (Campbell et al.
2010) compared to, for example, 1% of breast or ovarian cancer
rearrangements (Stephens et al. 2009; McBride et al. 2012).
Substitutions induced by aflatoxin B1 in wild-type and DNA
repair-deficient C. elegans
Many carcinogens drive cancer by directly modifying nucleotides,
leading to errors in either DNA replication or DNA repair. The spe-
cific chemistry of the mutagen and DNA dictates a rather stereotyp-
ical interaction, which reads out as a reproducible mutational sig-
nature in the genome that is distinctive for each carcinogen (Pfeifer
et al. 2002). We exploited the C. elegans model system to analyze
mutation spectra associated with three carcinogens across different
DNA repair deficiencies (Fig. 2A). In this protocol, we exposed in-
dividual mature hermaphrodites to the carcinogen and expanded
a single offspring derived from mutagenized male and female germ
cells for sequencing—each carcinogen-background combinationwas
performed in triplicate. The carcinogens were chosen to encompass
different types ofDNA lesion: aflatoxin causes bulkyDNAadducts on
guanine residues; mechlorethamine and cisplatin are reported to
cause a variety of monoadducts, intra- and interstrand crosslinks.
Aflatoxin B1 is a naturally occurring mycotoxin, produced by
Aspergillus flavus, a fungus linked to the development of many he-
patocellular carcinoma in sub-Saharan Africa and East Asia (Kensler
et al. 2011). Aflatoxin B1 is metabolized to the toxicologically
relevant epoxide, which preferentially attacks guanine residues
leading to bulky DNA adducts that are removed by nucleotide
excision repair (NER) (Smela et al. 2001). Aflatoxin B1, a mutagen
requiring metabolic activation, has been shown to be metabolized
and inflict DNA damage in C. elegans (Leung et al. 2010). Exposure
of C. elegans wild-type, NER mutants, and polq-1 translesion syn-
thesismutants to low doses of Aflatoxin B1 led to a slight reduction
in viability of embryos reaching 15%–20% embryonic lethality in
xpf-1 mutants (Supplemental Fig. S3A). Low doses of mutagen
exposure were chosen to avoid secondary mutagenic effects re-
lating to swamping the DNA damage response.
For the genomic analyses we sequenced the clonal progeny of
three independently derived F1 animals from each dose level of
Aflatoxin B1 (0 mM, 0.3 mM, and 3 mM) across six genetic back-
grounds. From the genome sequencing, we called newly acquired
mutations (Fig. 2B). There was a clear relationship between the
dose of aflatoxin and the number of base substitutions (P < 0.0001)
and a markedly uneven distribution across the six possible classes
of base substitution (P < 0.0001). C>T and C>A (equivalently, G>A
and G>T) changes were particularly prominent, consistent with
the known property of aflatoxin to generate adducts at guanines.
All NER deficiency backgrounds showed an increase in substi-
tutions compared to wild-type (P = 0.007). However, among the
different NER-deficient backgrounds, there was no significant dif-
ference in substitution rates (P = 0.3). Accumulation of mutations
without concomitant reduction in embryonic progeny survival
indicates that sequencing provides a more sensitive genotoxicity
assay than measuring reduced survival of progeny. The aflatoxin
signature matches mutation profiles reported in the TP53 gene in
human aflatoxin-induced hepatocellular carcinomas, namely, a
preponderance of C>T transitions and C>A transversions (equiv-
alently, G>A and G>T) occurring with a strand bias indicative of
evidence of transcription-coupled nucleotide excision repair
(Petitjean et al. 2007; Besaratinia et al. 2009).
In many carcinogen-induced cancers, the surrounding se-
quence context influences the mutation rate at adducted bases. We
therefore compared the distribution of bases around the mutated
base in aflatoxin-exposed animals to the expected distribution from
the reference genome (Fig. 2C). For mutations at C:G bases, we
found strong evidence for an enrichment of G immediately 59 to the
mutatedC (P < 0.0001) and immediately 39 (P = 0.0002). Statistically
significant biases in a sequence context were also found in muta-
tions at T:A pairs (P < 0.0001), albeit with much lower numbers.
Substitutions induced by crosslinking agents
mechlorethamine and cisplatin
Wenext investigatedmutational signatures induced by twowidely
used chemotherapeutic agents, mechlorethamine and cisplatin.
Mechlorethamine, a nitrogen mustard, induces monoadducts at
guanines and interstrand crosslinks, especially at CG:GC or GC:
CG dinucleotides (Povirk and Shuker 1994). Cisplatin is a plati-
num-based drug widely used in cancer chemotherapy. The plati-
num atoms form covalent bonds with purines resulting in 65%
GpG, 25% ApG, and 5%–10% GpNpG intrastrand crosslinks, as
well as a small percentage of interstrand crosslinks andmonoadducts
(Lemaire et al. 1991).Monoadducts are repaired by the base excision,
nucleotide excision, and mismatch repair pathways. Intrastrand
crosslinks are thought to be largely repaired by the NER pathway,
while the Fanconi anemia pathway, in conjunction with compo-
nents of the homologous recombination pathway and translesion
synthesis, are required to repair DNA interstrand crosslinks.
Treating germ cells with a moderate dose of mechlorethamine
and cisplatin resulted ina reductionof progeny survival, accentuated
Mutation profiling in C. elegans
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in DNA repair mutants (Supplemental Fig. S3B,C). In the genome,
mechlorethamine treatment caused a modest but statistically
significant increase in single-base substitutions compared to no
treatment controls (P = 0.04). Compared to wild-type, this dose-re-
sponse relationship was no more pronounced in knockouts of fan-1
or fcd-2 (Fig. 3A), genes encoding components of the Fanconi anemia
crosslink repair pathway. Indels and struc-
tural variants also substantially increased
with mechlorethamine exposure (P <
0.0001), as discussed later.
Cisplatin treatment caused a strik-
ing, dose-dependent increase in base sub-
stitutions (P < 0.0001) (Fig. 3B). This was
especially pronounced for C>Amutations,
but all classes of substitution increased in
frequency with cisplatin exposure. There
were significant differences in the muta-
tion prevalence depending on the genetic
background (P < 0.0001), largely relating
to an increase in substitutions for xpf-1
knockouts (P = 0.3 for differences across
the other backgrounds). This result is
consistent with the expected role of XPF-1
in nucleotide excision repair and intra-
strand crosslink repair.
As for aflatoxin, the local sequence
context strongly influences the mutage-
nicity of cisplatin (Fig. 4A). The base im-
mediately 59 to a mutated C (P < 0.0001)
and 39 (P < 0.0001) showed a different
distribution compared to the genome,
and there were significant differences
among the three different types of cyto-
sine mutation (P < 0.0001 for 59 base
context and P = 0.01 for 39 base). Thus,
C>Amutations were especially prominent
in a CpC context (equivalently, G>T in a
GpG context). However, in a TpC con-
text, C>T mutations were more pro-
nounced, suggesting that local sequence
context influences which incorrect base
is incorporated opposite a damaged
base. Similar findings applied to muta-
tions at thymine residues (P < 0.0001 for
difference from genome at 59 and 39
bases; P < 0.0001 and P = 0.01 for dif-
ferences across mutation types at 59 and
39 bases, respectively). Among the vari-
ous genetic backgrounds, there were
only minor differences in the local se-
quence context for cytosine mutations
(P = 0.05 and P = 0.07 for 59 and 39 base)
(Fig. 4B).
Taken together, across all three car-
cinogens, the signature of mutations ob-
served reflects the specific chemistry of a
mutagen’s interaction with a single base
or adjacent bases. The most frequent
intrastrand crosslink induced by cisplatin
is at GpG dinucleotides (Lemaire et al.
1991), and this matches the high rate of
C>A mutations in a CpC context (equiv-
alently, G>T in a GpG context). The interaction of mutagen and
base is modulated by subtle changes in local DNA shape rendered
by the sequence context. The acquisition of a mutation further
requires a failure of DNA repair, as evidenced by the high rate of
cisplatin-induced mutations in xpf-1 deficiency and aflatoxin-in-
duced mutations in NER deficiency.
Figure 2. Mutations in C. elegans exposed to carcinogens. (A) The experimental design exposed
a selfing animal to a specified dose of carcinogen and expanded progeny for whole-genome se-
quencing. The three carcinogens used were chosen because they generate different classes of DNA
lesions. (B) Numbers and distribution of acquired mutations across wild-type (WT) and different genetic
knockout lines exposed to different doses of aflatoxin. Each replicate worm is shown as a separate bar,
colored by the class of variant. (Del) Deletion; (Ins) insertion; (DI) complex indel; (SV) structural variant.
(C ) Surrounding sequence context for base substitutions in animals exposed to aflatoxin. The genomic
sequence from three bases upstream to three bases downstream from each observed mutation was




 Cold Spring Harbor Laboratory Press on January 8, 2018 - Published by genome.cshlp.orgDownloaded from 
Patterns of dinucleotide substitutions in C. elegans
and human tumors
Dinucleotide substitutions, where two adjacent bases are mutated,
were rare in both wild-type and DNA repair-deficient animals fol-
lowed for 20 generations (Fig. 5A). Similarly, they were not seen to
any great extent in worms treated with either aflatoxin or mech-
lorethamine (Fig. 5A). However, dinu-
cleotide substitutions were substantially
more frequent in C. elegans exposed to cis-
platin, especially in the context of xpf-1, but
also in fcd-2 and lig-4 (nonhomologous
end-joining) deficiency. The signature of
dinucleotide substitutions observed with
cisplatin showed some specificity, both
in which dinucleotides were mutated and
what they mutated to (Fig. 5B). The most
commonlymutated dinucleotide was CpT
(equivalently, ApG), followed by CpA
(TpG). These were most frequently trans-
formed to ApC dinucleotides in the form
of CT>AC or CA>AC mutations. The ob-
served substitution patterns match the
known chemistry of cisplatin, namely, that
intrastrand crosslinks comprise 65% GpG
and 25%ApG lesions (Lemaire et al. 1991).
In our data, the former appear to result in
G>T (equivalently, C>A) single nucleotide
substitutions (that is, GG>TG or GG>GT),
whereas the latter seem to cause dinucle-
otide substitutions (especially AG>GT).
Overall, then, dinucleotide substitu-
tions appear to be rather specific in their
origin. They are rare occurrences sponta-
neously, even in the setting of the DNA
repair deficiencies we analyzed. Moreover,
of the three carcinogens studied, only
cisplatin caused these events at apprecia-
ble rates. These data raise the hypothesis
that intrastrand crosslinks, the most fre-
quent lesion induced by cisplatin, may
be especially associated with dinucleotide
substitutions.
Signatures of dinucleotide substitu-
tions have not been explicitly explored in
human cancers. Given that such variants
are rare spontaneous events, we explored
whether any human tumors had specific
signatures of dinucleotide substitution.
We extracted dinucleotide substitutions
observed in 7042 cancer samples, com-
prising 6535 exomes and 507 whole ge-
nomes across 30 tumor types (Alexandrov
et al. 2013). Ranked by the overall fre-
quency of dinucleotidemutations perMb
sequenced, the tumor types with the
highest rates were melanoma, lung ade-
nocarcinoma, lung squamous, small cell
lung, and bladder cancers (Supplemental
Fig. S4A). Like the C. elegans experiments,
therewas specificity across tumor types in
both the dinucleotidesmutated andwhat
they mutated to (Supplemental Fig. S4B). In melanoma, the pre-
dominant pattern was CC>TT mutations, in keeping with ultra-
violet light inducing intrastrand covalent bonds between adjacent
cytosines, effectively an intrastrand crosslink. In the lung cancers,
the predominant dinucleotide substitution was CC>AA (GG>TT).
Acetaldehyde, one of the major chemical constituents of cigarette
smoke, induces this exact dinucleotide mutation signature in vitro
Figure 3. Mutations in C. elegans exposed to mechlorethamine (A) and cisplatin (B). Numbers and
distribution of acquired mutations across wild-type and different genetic knockout lines exposed to the
mutagen. Each replicate worm is shown as a separate bar, colored by the class of variant. (Del) Deletion;
(Ins) insertion; (DI) complex indel; (SV) structural variant.
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through the formation of intrastrand crosslinks at GpG (Matsuda
et al. 1998). That it is a carcinogen acting at GpG dinucleotides in
the lung cancers is further supported by a clear transcriptional
strand bias—1214 GG>TT events were observed on the non-
transcribed strand compared to 724 on the transcribed strand (P <
0.0001 for departure from a 50% split). This strand bias is in-
dicative of the action of transcription-coupled repair, which uti-
lizes the nucleotide-excision repair machinery (Bohr et al. 1985;
Mellon et al. 1987; Mellon and Hanawalt 1989). Thus, human
tumors with the highest rates of dinucleotide substitutions are
those associated with clear mutagen exposures.
Signatures of small insertions
and deletions
Both cisplatin andmechlorethamine treat-
ment led to a dramatic increase in the
number of small deletions compared to
untreated animals (Fig. 3), and a change
in their size distribution (Fig. 6A). De-
letions in the absence of mutagen, or
upon treatment with aflatoxin, tended to
be 1–2 bp or >20 bp in size, whereas we
observed a much more uniform distribu-
tion of sizes for mechlorethamine and
cisplatin. As might be expected for the
known chemistry of these latter two
agents, the deletions tended to affect
guanine-rich sequences (Fig. 6B).
There were interesting differences
across the various genetic backgrounds.
Indel numberswere somewhat reduced in
animals lacking the SLX-1 or MUS-81
nucleases involved in homologous re-
combination, the LIG-4 DNA end-joining
ligase or the POLQ-1 translesion poly-
merase (Fig. 3). This suggests that these
proteins might have a role in the gener-
ation of indels upon cisplatin exposure.
This hypothesis is further supported by
the observation that the extent of micro-
homology at the indel was reduced in lig-4
and lig-4; fcd-2 knockout lines (Fig. 6C).
For these two lines, only one of 22 indels
had flanking microhomology, compared
to 30/100 for the other lines combined
(P = 0.01). These data suggest that dele-
tions with no detectable microhomology
are generated via lig-4-dependent DNA
end-joining. We also note that the num-
ber of complex rearrangements and indels
is reduced in lig-4; fcd-2 double mutants
compared to knockouts of fcd-2 alone.
This finding provides molecular evidence
that inappropriate end-joining of broken
DNA strands occurring as a repair in-
termediate during interstrand crosslink
excision contributes to chromosomal al-
terations. Our results corroborate previous
findings demonstrating that the reduced
survival of Fanconi anemia-deficient cells
in response to crosslinking agents is sup-
pressed by eliminating nonhomologous
end-joining (Adamo et al. 2010; Pace et al. 2010). On the other
hand, our results also suggest that NHEJ might help in sealing some
ICL lesions, leading to a positive outcome of ICL repair.
Complex genomic rearrangements caused by interstrand
crosslinks, fork stalling, and template switching
Among structural variants identified in these experiments, we
found several examples of multiple rearrangements tightly clus-
tered in one or a few genomic regions (Fig. 7; Supplemental Fig. S5).
These occurred in C. elegans treated with mechlorethamine or
Figure 4. Sequence context for base substitutions observed in cisplatin-treated C. elegans. (A) Sur-
rounding sequence context for cytosine and thymine substitutions in animals exposed to cisplatin, split
by type ofmutation. The genomic sequence from three bases upstream to three bases downstream from
each observedmutation was aggregated and presented as proportions in a stacked bar chart, compared
to the reference genome. (B) Surrounding sequence context for cytosine and thymine substitutions in
animals exposed to cisplatin, split by genetic background. The genomic sequence from three bases
upstream to three bases downstream from each observed mutation was aggregated and presented as
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cisplatin, but not in animals exposed to aflatoxin or followed for
20 generations without mutagen exposure. The clusters in car-
cinogen-treated worms differed from those described earlier in the
mrt-2-deficient background (Fig. 1C–E) in that they occurred any-
where within a chromosome rather than being limited to telo-
meric regions. Interestingly, clusters occurred in animalswithDNA
repair defects such as xpf-1 (Fig. 7A) or fan-1 deficiency (Supple-
mental Fig. S5), but they clearly also arose in a wild-type back-
ground exposed to crosslinking agents (Fig. 7B,C). Thus, in-
terstrand crosslinks appear to be strongly linkedwith this signature
of clustered structural variants, possibly an outcome of blocked
DNA repair intermediates, with the resulting genomic disruption
worsened by defects in crosslink repair.
Several genomic features of these events argue that the clus-
tered rearrangements result from a replication-based mechanism,
such as fork stalling and template switching, dubbed ‘‘chromo-
anasynthesis’’ (Liu et al. 2011b). First, by virtue of the experimental
design, each cluster must have occurred in a single catastrophic
event in the germ cell, since each replicate was only exposed
transiently to the mutagen at a critical stage of the life cycle. Sec-
ondly, unlike chromothripsis, which is fundamentally a deletion
Figure 5. Patterns of dinucleotide substitutions observed. (A) Numbers
of dinucleotide substitutions in animals propagated for 20 generations
and those exposed to the different carcinogens. (B) Dinucleotide sub-
stitutions in cisplatin-exposed animals. The sequences of the dinucleotides
that are mutated are on the x-axis and what they are mutated to is
denoted by the color of the bar.
Figure 6. Patterns of indels observed. (A) Histogram of the size of de-
letions observed across the different experimental designs. (B) Histogram
of the most frequently observed small deletions across the different ex-
periments. (C ) Distribution of repeat-mediated, microhomology-medi-
ated, or blunt end-joining deletions by different genetic backgrounds. The
difference between lig-4-deficient and other mutant backgrounds for the
number of blunt end-joining deletions is significant (P = 0.01).
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mechanism (Korbel and Campbell 2013), the events observed
here were associated with multiple regions of chromosomal gain
that suggest a replicative process. For example, in one wild-type
animal exposed tomechlorethamine, we saw two regions of copy
number 3 and one of copy number 5 created by the rearrangements
(Fig. 7C). Given that this occurred in a single germ cell, there must
have been at least two rounds of over-replication in the same S
phase to generate a copy number of 5. Thirdly, there is striking
clustering of breakpoints within several regions even across dif-
ferent chromosomes, with multiple examples of rearrangements
crossing back and forth between these regions (Fig. 7A). This pat-
tern indicates that template switching can occur many times
during the resolution of the chromosomal crisis, but is limited to
discrete genomic regions. Fourthly, persis-
tent interstrand DNA crosslinks con-
ferred by mechlorethamine and cisplatin
are known to impede the progress of DNA
polymerases (Knipscheer et al. 2009), and
hence place replication fork stalling and
template switching at the center of this
process.
We postulate that each region af-
fected by clustered rearrangements might
result from as little as one persistent DNA
crosslink. The massive scale of genomic
disruption in these regions suggests that
the most cytotoxic effects of mechlor-
ethamine and cisplatin derive from such
unrepaired, persistent crosslinks. The num-
ber of complex rearrangements is highly
variable across replicates in the cisplatin-
treated animals (Figs. 3, 7).We expect that
such rearrangements confer increased
lethality. The fluctuation in progeny sur-
vival between single cisplatin-treated ani-
mals hints that complex rearrangements
might be the most lethal lesions (Supple-
mental Fig. S6).
Replication fork stalling and tem-
plate switching has been hypothesized
to underpin some of the complex geno-
mic rearrangements found in consti-
tutional genomic disorders (Liu et al.
2011b). One study, for example, showed
that 19% of individuals with chromo-
somal abnormalities had evidence for
complexity of genomic rearrangements at
the breakpoints (Chiang et al. 2012). In
many cases, these complexes of structural
variation are driven by clustered rear-
rangements with a striking resemblance
to those described here, and cause severe
developmental disorders (Liu et al.
2011b). Our data provide evidence
from an experimental model for the
proposed fork stalling and template
switching mechanism, and identify
persistent interstrand crosslinks as an
important potential etiologic agent for
these events. This is of particular in-
terest given the recent report that en-
dogenous crosslinking agents, such as
alcohol-derived aldehydes, can cause genotoxic damage inmice
(Langevin et al. 2011) and are associated with esophageal cancer
(Brooks et al. 2009).
Discussion
We have used C. elegans as an experimental system to study the
effects of carcinogens and DNA repair deficiencies on mutational
signatures, and their interactions. Mutation profiles obtained from
the three carcinogens differ in several key aspects, faithfully
reflecting the known chemistry of these agents. Aflatoxin B1, asso-
ciated with monoadducts on guanines, causes a mutational signa-
ture characterized by single base G>T and G>A substitutions, and
Figure 7. Chromoanasynthesis in animals treated with crosslinking agents. (A) Copy-number profile
and genomic rearrangements observed on chromosomes I, II, IV, and V for an xpf-1-deficient animal
treatedwith cisplatin. (B) Copy-number profile and genomic rearrangements observed on chromosomeX
for a wild-type animal exposed to mechlorethamine. (C ) Copy-number profile and genomic rearrange-
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few dinucleotide substitutions, indels, or structural variants. The
substitutions are influenced by the local sequence context, and in-
crease when genes critical to the nucleotide excision repair pathway
are absent. Mechlorethamine, causing interstrand crosslinks, has a
relatively modest effect on rates of single or double nucleotide
substitutions, but is instead associated with a marked increase in
small deletions and complex genomic rearrangements indicative of
replication fork stalling and template switching. Finally, cisplatin,
inducing a mixture of intrastrand crosslinks, interstrand crosslinks,
andmonoadducts, generates an equally complexmix ofmutations,
with increased rates of single base and dinucleotide substitutions,
indels, and structural variants. Deficiencies in crosslink repair have
variable consequences on the rates of these events, withXPF-1 being
particularly critical to protection against the genotoxic effects of
cisplatin. Intriguingly, increased expression of the XPF regulatory
subunit ERCC1 is correlated with poor prognosis upon cisplatin
treatment in human cancers (Dabholkar et al. 1994; Shirota et al.
2001; Lord et al. 2002;Hoand Scharer 2010),which chimeswith our
experimental findings.
The Environmental Protection Agency currently scores 240
chemicals for potential carcinogenicity, of which 11 and 72 are
recorded as definite and probable human carcinogens, respectively
(http://www.epa.gov/iris/). Of the 240 chemicals, 116 cannot be
classified because available data are too limited. We believe geno-
mics offers an effective approach to augment these analyses. Many
(but not all) carcinogens act through increasing the mutation rate
in exposed tissues. We have shown here and elsewhere (Pleasance
et al. 2010a,b; Alexandrov et al. 2013) that mutational signatures
associated with carcinogens have a high degree of specificity when
assessed across the several dimensions of single base changes, di-
nucleotide substitutions, indels, and structural variants; effects of
the local sequence context; and imprints of DNA repair such as
transcriptional strand bias. In a genomics-focused approach, a can-
didate carcinogen could be assessed by sequencing human cancers
with documented exposures coupled with parallel assessment in an
experimental system such as theC. elegansmodel outlinedhere.Our
model will allow the detection of specific profiles that may trigger
early stages of carcinogenesis, but in tumors are later superseded by
further signatures, possibly linked to acquiredmutator phenotypes.
To ascertain the safety of new compounds is amajor challenge
of the pharmaceutical, cosmetic, and food industries. Current
standard procedures for genotoxicity testing are rather limited. The
widely used bacterial Ames assay is based on the reversion fre-
quency of a single gene (Ames 1979). Alternative assays such as
micronuclei counts or the comet assay only uncover large-scale
genomic alterations (for review, see Fenech et al. 2011). Whole-
genome sequencing of model organisms, both wild-type and DNA
repair deficient, would significantly enlarge the repertoire of geno-
toxicity assays. C. elegans provides the advantage of being more
closely related to human systems using DNA repair and apoptosis
modalities not conserved in budding or fission yeast. Many carcino-
gens need to be metabolically activated by cytochrome P450
enzymes. A large number of these enzymes are conserved in nem-
atodes, and members of the cytochrome P450 group I enzymes,
which are missing in the nematode genome, could be expressed in
C. elegans (Leung et al. 2010). Genome-wide assays will also be
useful in the field of DNA repair. The direct measurement of DNA
lesions has historically been restricted to locus-specific reporter
assays. Defects associated with a given DNA repair pathway are
conventionally assayed by showing decreased viability of the
corresponding knockout when treated with genotoxic agents.
However, decreased viability does not necessarily correlate with
defects in genome integrity, and genome sequencing will provide
a muchmore explicit description of the degree and nature of defects
in genome maintenance. Next-generation sequencing provides an
accurate measurement of fixed DNA damage; the nature of DNA
damaging agents and how these are handled in intact or repair-de-
ficient backgrounds affects mutation frequency and mutational
profiles. Examining repair modalities, where DNA repair inter-
mediates can be visualized as distinct repair foci, as can be donewith
the RAD-51 recombinase during homologous recombination, will
allow for a more precise correlation of actual DNA damage, the ef-
ficiency of repair and the ultimate repair outcome at the level of the
genome.Ultimately, though, the sequencing approachoutlinedhere
is correlative, not definitive—our hope is that coupling these large-
scale screens with experimental systems such as C. elegans will gen-
erate hypotheses and guide experiments into the mechanistic basis
for our observations.
With sequencing of thousands of cancer andnormal genomes
now complete, mutational signatures are being dissected and char-
acterized at a pace and scale that evokes the revolution in taxonomy
of species sparked by Linnaeus. Currently, however, the taxonomy
of mutational signatures is too often Aristotelian, based on a geno-
mic ‘‘morphology’’ rather than a deep understanding of the un-
derlying causative mechanisms. As we develop systematic catalogs
of mutation signatures associated with chemicals and DNA repair
defects in experimental systems such as described here, we will in-
creasingly be able to explain the etiology of human cancer genomes
in mechanistic detail.
Methods
C. elegans strains and maintenance
Strains were grown at 20°C under standard conditions (Brenner
1974) unless indicated otherwise. The N2 Bristol reference line
TG1813 is used in theGartner laboratory as thewild-type reference
strain. All mutant strains were backcrossed six times to TG1813.
Strains are listed in Supplemental Table S1.
C. elegans propagation for mutation accumulation
To study the accumulation of mutations over several generations,
starved F2 plates (first generation homozygous) from the sixth
backcross were split onto two large plates and frozen for glycerol
stocks and genomic DNA preparation (P0 generation) (Fig. 1A). In
parallel, five single L4 stage animals were randomly chosen from
these plates and singled each genotype (F1). After every 3–4 d, one
single L4 stage animal was randomly chosen among the progeny
per plate and propagated. This procedure was repeated until the
F20 generation (Fig. 1A). Lines were frozen at generations P0, F5,
F10, F15, and F20 for DNA isolation and glycerol stocks. Genomic
DNA was sequenced from the P0 and F20 generation.
C. elegans intoxication
To assess drug sensitivity, 20–30 young adult hermaphrodites were
packed into2mLof Sbasal + 5mL concentratedOP50bacteria in a24-
well plate. Aflatoxin B1, mechlorethamine hydrochloride, and cis-
platin (all Sigma-Aldrich) solutions were freshly prepared and added
to indicated concentrations. Animals were incubated under gentle
shaking for 16 h at 20°C and then transferred to plates to recover.
Progeny viability was scored 22–24 h post-treatment as described
previously (Collis et al. 2006). Single offspring (derived from muta-
genized male and female germ cells) from three individual adults of
each genotype and carcinogen dose were expanded for sequencing.
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Genomic DNA isolation
Animals were washed from 9-cm 33NGM plates within 12 h post-
starvation, washed three times 10 min in M9 buffer, and frozen in
liquid nitrogen. Genomic DNA was isolated using ChargeSwitch
gDNAMini Tissue Kit (Invitrogen). DNA quality was determined by
agarose gel electrophoresis and quantified using a Qubit Fluorom-
eter (Invitrogen) or photometric OD260/OD280 measurement.
Minimally, 5 mg DNA of each sample was used for whole-genome
sequencing.
DNA sequencing
Genomic DNAwas shotgun sequenced on an Illumina HiSeq 2000
platform in pools of five to six samples per lane. Library prepara-
tion followedmanufacturer protocols andwas sequenced at 100 bp
paired-end.
Bioinformatic analysis
Raw sequencing reads were aligned to the reference C. elegans ge-
nome (buildWS220/ce10) using the BWA algorithm (Li andDurbin
2009). For every ‘‘test’’ worm (that is, a worm exposed to carcinogen
or followed for 20 generations),we identified a ‘‘control’’ worm (that
is, one with the same genetic background, but not exposed or fol-
lowed for 20 generations). Base substitutions, indels, genomic re-
arrangements, and copy-number changes acquired in the ‘‘test’’
worm, not found in the ‘‘control’’ worm,were called using a series of
in-house algorithms described in detail elsewhere (Nik-Zainal et al.
2012a,b). From the raw output of these pipelines, we ran a series of
post-processing filters developed specifically for this project, in or-
der to produce a set of variant calls with high positive predictive
value (see Supplemental Material for details).
Statistical analysis
To compare numbers of mutations across different genetic back-
grounds, carcinogen doses, and types of mutations, we used gen-
eralized linear mixed effects models. Essentially, these models
allow for correlations in the numbers of mutations of each differ-
ent type within a given worm while enabling formal hypothesis
testing (likelihood ratio tests) of questions of interest. To compare
differences in sequence context, x2 tests were used. To estimate the
mutation rate per generation per genome in the 20-generation
experiment, we used the maximum likelihood estimate from the
observed number of mutations, assuming that with each genera-
tion a heterozygousmutation has a 25% chance of becoming fixed
and homozygous, a 50% chance of remaining heterozygous, and a
25% chance of being lost.
Data access
Sequencing data generated for this study have been submitted to
the EuropeanNucleotide Archive (ENA; http://www.ebi.ac.uk/ena/)
under study accession number ERP000975.
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